The objective of this study was to observe and evaluate the efficacy and safety of hexapopal ethanolamine tablets in the treatment of synchronous/sequential radioimmunoinduced thrombocytopenia in the real world.
The subjects of this study were patients with solid malignant tumors who had received radioimmunoinduced thrombocytopenia.
This study will retrospectively and prospectively collect real-world data related to investigational drugs, and will observe 500 patients to observe the diagnosis and treatment pattern of radiochemo-induced thrombocytopenia. The study included a screening period (no more than one week) and a treatment period (at least two cycles).Participants meeting protocol inclusion criteria were defined as having platelet values \< 100×109/L during radioimmunotherapy.
Understand the research procedure and voluntarily sign the informed consent to participate in the study
Subjects ≥18 years of age receiving synchronous/sequential chemotherapeutic therapy
Patients with platelet count ≤100×109/L or platelet count decrease ≥ 50×109/L or platelet count > 100×109/L but need to be prophylaxis with hexapopethanolamine tablets
Researchers believe that subjects need to be treated with hexapopal.
The subjects are conducting clinical intervention studies
Patients with known or expected allergy or intolerance to the active ingredient or excipient of hexapopar
Pregnant or lactating women
Other conditions deemed unsuitable for inclusion in the study by the researcher.
Patients with solid malignancies undergoing radiotherapy/chemotherapy/immunosuppressant induced thrombocytopenia
Cohort
Prospective
Herombopag Olamine Tablets
DrugHerombopag Olamine；combined rhTPO;combined IL-11
The proportion of patients recovered to 100×109/L
The proportion of patients who recovered to 100×109/L within 14 days after starting treatment with the drug was studied
The proportion of patients recovered to 75×109/L
The proportion of patients who recovered to 75×109/L after starting treatment with the drug was studied
Time for platelet recovery to 100×109/L
Study the time for platelet recovery to 100×109/L after drug initiation
Proportion of patients with treatment delay or dose reduction
Proportion of patients with delayed or reduced dose of radiotherapy, chemotherapy, immunosuppressants, etc
TRAE
Study drug-related adverse reactions
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
